for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Beigene Ltd (ADR)

BGNE.O

Latest Trade

285.89USD

Change

0.00(0.00%)

Volume

33

Today's Range

--

 - 

--

52 Week Range

118.55

 - 

322.98

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
285.89
Open
0.00
Volume
33
3M AVG Volume
5.32
Today's High
--
Today's Low
--
52 Week High
322.98
52 Week Low
118.55
Shares Out (MIL)
1,182.92
Market Cap (MIL)
24,153.12
Forward P/E
-16.84
Dividend (Yield %)
--

Next Event

Q4 2020 Beigene Ltd Earnings Release

Latest Developments

More

Beigene Says NMPA Approves XGEVA

Beigene Says Board Approved A Preliminary Proposal For Possible Issue Of RMB Shares

Beigene Says Biologics License Application For Qarziba Accepted By China NMPA & Granted Priority Review

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Beigene Ltd (ADR)

BeiGene, Ltd. is principally engaged in biopharmaceutical business. The Company is mainly engaged in the research and development, production and sales of innovative molecularly targeted and immuno-oncology drugs for the treatment of cancer. The Company's main products include Zanubrutinib (BGB-3111), Tislelizumab (BGB-A317) and Pamiparib (BGB-290).

Industry

Biotechnology & Drugs

Contact Info

C/O Mourant Governance Services (Cayman)

94 Solaris Avenue, Camana Bay

BEIJING, BEJ

102206

China

+1.345.9494123

Executive Leadership

John Victor Oyler

Co-Founder, Executive Chairman of the Board, Chief Executive Officer

Xiaobin Wu

General Manager - China, President

Xiaodong Wang

Co-Founder, Non-Executive Director

Jane Huang

Chief Medical Officer, Hematology

Hing Ling Chau

Company Secretary

Key Stats

2.27 mean rating - 15 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2017

0.2K

2018

0.2K

2019

0.4K

2020(E)

0.3K
EPS (USD)

2017

-2.230

2018

-12.150

2019

-15.800

2020(E)

-17.054
Price To Earnings (TTM)
--
Price To Sales (TTM)
90.92
Price To Book (MRQ)
6.07
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
4.71
LT Debt To Equity (MRQ)
3.53
Return on Investment (TTM)
-48.51
Return on Equity (TTM)
-42.41

Latest News

Latest News

China's BeiGene to start human testing of COVID-19 antibody treatment in September

China-based drugmaker BeiGene Ltd said on Thursday that an early-stage human study to test its COVID-19 antibody treatment will begin in September.

BRIEF-Beigene Says Began Commercializing Xgeva (Denosumab) In China

* ON JUNE 30, CO BEGAN COMMERCIALIZING XGEVA (DENOSUMAB) IN CHINA FOR TREATMENT OF GIANT CELL TUMOR OF BONE Source text https://bit.ly/2ZpQivq Further company coverage:

BRIEF-BeiGene Announces Acceptance Of Supplemental New Drug Application For Tislelizumab

* BEIGENE ANNOUNCES ACCEPTANCE OF A SUPPLEMENTAL NEW DRUG APPLICATION FOR TISLELIZUMAB IN PATIENTS WITH PREVIOUSLY TREATED UNRESECTABLE HEPATOCELLULAR CARCINOMA IN CHINA Source text for Eikon: Further company coverage:

BRIEF-Beigene And Springworks Announce Presentation Of Preclinical Data From Solid Tumors Treatment

* BEIGENE AND SPRINGWORKS ANNOUNCE PRESENTATION OF PRECLINICAL DATA COMBINING RAF DIMER INHIBITOR LIFIRAFENIB WITH MEK INHIBITOR MIRDAMETINIB AND PROVIDE UPDATE ON ONGOING PHASE 1B/2 CLINICAL TRIAL

BRIEF-BeiGene Announces European Medicines Agency Acceptance Of Marketing Authorization Application For BRUKINSA

* BEIGENE ANNOUNCES EUROPEAN MEDICINES AGENCY ACCEPTANCE OF ITS MARKETING AUTHORIZATION APPLICATION FOR BRUKINSA® (ZANUBRUTINIB) FOR THE TREATMENT OF PATIENTS WITH WALDENSTRÖM’S MACROGLOBULINEMIA Source text for Eikon: Further company coverage:

BRIEF-Beigene Reports Approval Of Brukinsa In China For Small Lymphocytic Lymphoma

* BEIGENE ANNOUNCES THE APPROVAL OF BRUKINSA™ (ZANUBRUTINIB) IN CHINA FOR PATIENTS WITH RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA OR SMALL LYMPHOCYTIC LYMPHOMA AND RELAPSED/REFRACTORY MANTLE CELL LYMPHOMA

BRIEF-Beigene Says Aspen Trial Did Not Achieve Statistical Significance On Its Primary Endpoint

* ASPEN TRIAL DID NOT ACHIEVE STATISTICAL SIGNIFICANCE ON ITS PRIMARY ENDPOINT Source text for Eikon: Further company coverage:

BRIEF-Beigene Presents Phase 3 Data On Tislelizumab Combined With Chemotherapy For The Treatment Of Patients With Advanced Squamous Non-Small Cell Lung Cancer

* BEIGENE PRESENTS PHASE 3 DATA ON TISLELIZUMAB COMBINED WITH CHEMOTHERAPY FOR THE TREATMENT OF PATIENTS WITH ADVANCED SQUAMOUS NON-SMALL CELL LUNG CANCER AT THE 2020 AMERICAN SOCIETY OF CLINICAL ONCOLOGY (ASCO) VIRTUAL SCIENTIFIC PROGRAM

BRIEF-Beigene Presents Updated Results From Phase 3 Trial Of Zanubrutinib vs Ibrutinib In Patients With Waldenström’S Macroglobulinemia

* BEIGENE PRESENTS UPDATED HEAD TO HEAD RESULTS FROM PHASE 3 TRIAL OF ZANUBRUTINIB VERSUS. IBRUTINIB IN PATIENTS WITH WALDENSTRÖM’S MACROGLOBULINEMIA AT THE 2020 AMERICAN SOCIETY OF CLINICAL ONCOLOGY (ASCO) VIRTUAL SCIENTIFIC PROGRAM Source text for Eikon: Further company...

BRIEF-Hutchison China MediTech Says Co, Beigene Enter Into Clinical Collaboration

* CHI-MED, BEIGENE ENTER INTO CLINICAL COLLABORATION TO EVALUATE COMBINATIONS OF SURUFATINIB, FRUQUINTINIB WITH TISLELIZUMAB

BRIEF-Beigene And Medison Pharma Announce Exclusive Distribution Agreement And Acceptance Of New Drug Application For Btk Inhibitor Brukinsa™ In Israel

* BEIGENE AND MEDISON PHARMA ANNOUNCE EXCLUSIVE DISTRIBUTION AGREEMENT AND ACCEPTANCE OF NEW DRUG APPLICATION FOR BTK INHIBITOR BRUKINSA™ (ZANUBRUTINIB) IN ISRAEL Source text for Eikon: Further company coverage: (Reuters.Briefs@thomsonreuters.com)

BRIEF-IGM Biosciences, Atreca, Beigene To Collaborate To Help Address Covid-19

* IGM BIOSCIENCES INC - ATRECA, INC. BEIGENE, LTD. AND IGM BIOSCIENCES, INC. ANNOUNCED THEIR PLANS TO COLLABORATE TO HELP ADDRESS COVID-19 PANDEMIC

BRIEF-Beigene Ltd Says CEO John V. Oyler's 2019 Total Compensation Was $12.6 Mln Vs $27.9 Mln In 2018

* BEIGENE LTD - CEO JOHN V. OYLER'S 2019 TOTAL COMPENSATION WAS $12.6 MILLION VERSUS $27.9 MILLION IN 2018 - SEC FILING

BRIEF-Beigene Announces Acceptance Of Supplemental New Drug Application For Tislelizumab In China

* BEIGENE ANNOUNCES ACCEPTANCE OF A SUPPLEMENTAL NEW DRUG APPLICATION FOR TISLELIZUMAB IN COMBINATION WITH CHEMOTHERAPY IN FIRST-LINE ADVANCED SQUAMOUS NON-SMALL CELL LUNG CANCER IN CHINA

BRIEF-Beigene Says Phase 3 Trial Evaluating Anti-PD-1 Antibody Tislelizumab Met Primary Endpoint

* PHASE 3 TRIAL EVALUATING ANTI-PD-1 ANTIBODY TISLELIZUMAB COMBINED WITH PEMETREXED AND PLATINUM CHEMOTHERAPY MET PRIMARY ENDPOINT

BRIEF-Beigene Announces Positive results from Lung Cancer Trial

* BEIGENE ANNOUNCES THAT THE PHASE 3 TRIAL OF TISLELIZUMAB COMBINED WITH CHEMOTHERAPY IN PATIENTS WITH FIRST-LINE NON-SQUAMOUS NON-SMALL CELL LUNG CANCER MET THE PRIMARY ENDPOINT OF PROGRESSION-FREE SURVIVAL AT INTERIM ANALYSIS

BRIEF-China Approves Beigene’s Tislelizumab For Patients With Previously Treated Carcinoma

* CHINA NATIONAL MEDICAL PRODUCTS ADMINISTRATION APPROVES BEIGENE’S TISLELIZUMAB FOR PATIENTS WITH PREVIOUSLY TREATED LOCALLY ADVANCED OR METASTATIC UROTHELIAL CARCINOMA

BRIEF-Beigene Posts FY Net Loss Attributable $948.6 Million

* FY NET LOSS ATTRIBUTABLE $948.6 MILLION VERSUS LOSS OF $673.8 MILLION

BRIEF-Beigene Says Celgene Corp Initiated Voluntary Recall Of All Existing Stock Of Abraxane In Mainland China

* CELGENE CORP INITIATED A VOLUNTARY RECALL OF ALL EXISTING STOCK OF ABRAXANE IN MAINLAND CHINA Further company coverage:

BRIEF-Beigene Announces Supply Update For ABRAXANE In China

* BEIGENE LTD - NMPA HAS SUSPENDED IMPORTATION, SALES AND USE OF ABRAXANE IN CHINA SUPPLIED BY CELGENE CORPORATION

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up